Welcome to our dedicated page for Rallybio SEC filings (Ticker: RLYB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Rallybio鈥檚 SEC disclosures dig deep into clinical trial milestones, R&D burn rates, and licensing payments鈥攙ital details that often hide in hundreds of technical pages. If you have ever asked, 鈥淗ow do I sift through Rallybio SEC filings explained simply?鈥� the challenge is clear: biotech documents demand both scientific and financial fluency.
Stock Titan solves this problem with AI-powered summaries that translate every Rallybio quarterly earnings report 10-Q filing, Rallybio annual report 10-K simplified, and Rallybio 8-K material events explained into plain language. AG真人官方-time alerts surface Rallybio insider trading Form 4 transactions the moment they hit EDGAR, while side-by-side comparisons flag changes in cash runway or trial timelines between periods. Our platform covers every form鈥擲-3 shelf registrations that hint at future capital raises, DEF 14A Rallybio proxy statement executive compensation details, and of course the critical Rallybio Form 4 insider transactions real-time.
Use cases investors rely on daily include:
- Tracking executive stock sales to gauge leadership confidence
- Spotting clinical development updates within 8-Ks before market reaction
- Comparing quarter-over-quarter R&D expenses via AI-tagged line items
- Reviewing dilution risk from equity offerings in one click
Whether you type 鈥渦nderstanding Rallybio SEC documents with AI鈥� or search for 鈥淩allybio earnings report filing analysis,鈥� you鈥檒l land on the same outcome鈥攁ctionable insight without wading through biotech jargon. Save hours and make informed decisions with comprehensive coverage, expert context, and AI clarity always up to date.
Rallybio Corporation (NASDAQ: RLYB) has divested its 50 % ownership in RE Ventures I, LLC (the ENPP1 joint venture) to Recursion Pharmaceuticals for immediate and potential future consideration.
- Initial consideration: Recursion issued 1,457,952 Class A shares (VWAP $5.1442) valued at $7.5 million on 8 July 2025.
- Make-whole mechanism: If Rallybio鈥檚 net proceeds from selling the Initial Shares differ from $7.5 million, the party benefiting must true-up the difference in cash.
- Contingent equity: Upon achievement of specified development milestones for the ENPP1 compound, Rallybio may receive additional shares worth up to $12.5 million, with the same make-whole feature.
- Milestone & royalty stream: The agreement grants Rallybio undisclosed cash milestone payments and low-single-digit royalties on future net sales of ENPP1-related products.
- Following the sale, the ENPP1 JV becomes an indirect wholly-owned subsidiary of Recursion; Rallybio relinquishes all equity interest.
The transaction strengthens Rallybio鈥檚 liquidity with $7.5 million in equity that can be monetised, de-risks ongoing ENPP1 development costs, and leaves upside through contingent consideration and royalties. However, future value now depends on milestones achieved by Recursion, and Rallybio forgoes direct participation in the JV鈥檚 long-term upside.
Rallybio (NASDAQ:RLYB) filed an 8-K announcing a new employment agreement with Chief Medical Officer Steven Ryder, M.D.
Key terms
- Base salary: $531,227
- Annual target bonus: 40% of salary
- Initial one-year term with automatic one-year renewals
- Standard severance: 12 months salary, prior bonus and up to 12 months COBRA
- Change-in-control severance: 1.5脳 salary + target bonus, 18 months COBRA and full vesting of time-based equity
Severance requires a release of claims; a 12-month non-compete and non-solicitation applies. No other operational or financial updates were disclosed.
FAQ
What is the current stock price of Rallybio (RLYB)?
What is the market cap of Rallybio (RLYB)?
What is Rallybio Corp's primary focus?
How does Rallybio approach drug development?
Which therapeutic areas does Rallybio target?
What sets Rallybio apart in the biotechnology industry?
What role does scientific expertise play at Rallybio?
Where is Rallybio located and how does its location benefit the company?
How does Rallybio ensure the robustness of its clinical candidates?
How does Rallybio compare with other clinical-stage biotechnology companies?
